周一， 英伟达 与 礼来 宣布成立首个专注于将人工智能应用于药物研发挑战的联合创新实验室。该实验室将汇集礼来在药物发现、开发与制造方面的全球领先专业知识，以及英伟达在人工智能、加速计算和AI基础设施方面的技术优势。双方计划在未来五年投入最多10亿美元用于人才、基础设施和计算资源。
英伟达CEO黄仁勋表示：“人工智能正在变革各行各业，其最深远的影响将体现在生命科学领域。英伟达与礼来正在汇聚各自行业的优势，开创药物研发的新蓝图——在这个模式下，科学家可以在计算机模拟中探索广阔的生物和化学空间，而无需先制造单一分子。”
礼来 小幅拉升涨逾1%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
